Financial Performance - Total revenues decreased by 58.81% from $13,207,000 in Q3 2023 to $5,440,000 in Q3 2024[316]. - Total revenues for the nine months ended September 30, 2024, were US$18.0 million, a decrease of US$23.6 million, or 56.74%, compared to the same period in 2023[341]. - The Distribution Business contributed 84.43% of total revenue for the nine months ended September 30, 2024, with a significant revenue decrease of US$22.4 million, or 59.51%[342]. - Distribution Business revenue fell by 60.42%, from $11,876,000 in 2023 to $4,701,000 in 2024, contributing 86.42% of total revenue[318]. - Life insurance revenue dropped by 64.82%, from $11,147,000 in 2023 to $3,921,000 in 2024[319]. - For the nine months ended September 30, 2024, the company reported a net loss of approximately US$28.8 million, with total revenue declining to approximately US$18.1 million from US$41.7 million in the same period of 2023[384][385]. Operating Expenses - Total operating expenses decreased by 36.36% from $24,550,000 in Q3 2023 to $15,623,000 in Q3 2024[316]. - Total operating expenses decreased by US$34.2 million, or 43.82%, for the nine months ended September 30, 2024, compared to the same period in 2023[340]. - Commission expense decreased by 78.31%, from $8,916,000 in 2023 to $1,934,000 in 2024[323]. - Personnel and benefit expenses decreased by 45.44%, from $6,446,000 in 2023 to $3,517,000 in 2024[328]. - Sales and marketing expense decreased by US$2.5 million, or 80.61%, from US$3.1 million in 2023 to US$0.6 million in 2024[347]. - Legal and professional fees decreased by US$7.0 million, or 56.35%, for the nine months ended September 30, 2024, primarily due to a reduction in consulting fees[352]. - Total other general and administrative expenses increased by US$1.2 million, or 53.48%, for the nine months ended September 30, 2024, mainly due to increased depreciation on right-of-use assets and interest expense on lease liabilities[355]. Cash Flow and Capital - As of September 30, 2024, the cash balance was US$5.1 million, with a working capital deficit of US$40.5 million, an increase of US$18.3 million or 82.21% from December 31, 2023[375]. - Net cash used in operating activities was US$20.7 million for the nine months ended September 30, 2024, compared to US$33.4 million for the same period in 2023[376]. - Net cash used in operating activities for the nine months ended September 30, 2024, was primarily due to the net loss and various decreases in liabilities, totaling US$28.8 million[377]. - Net cash provided by investing activities for the nine months ended September 30, 2024, was US$2.6 million, primarily from proceeds of US$2.2 million from the sale of long-term investments[379]. - Net cash provided by financing activities for the nine months ended September 30, 2024, was US$18.3 million, mainly due to advances from the holding company of US$15.6 million and proceeds from convertible promissory notes of US$23.4 million[381]. - The company intends to raise additional capital through various debt and equity offerings, but there is no assurance that these funds will be available on acceptable terms[387]. Strategic Initiatives - The Company plans to transform JFA into the best medical care institution in Asia by 2025, focusing on technology and data analytics to improve patient care[314]. - The Company aims to expand its distribution footprint in Mainland China and expects sales volumes to return to pre-pandemic levels with the reopening of the border[299]. - The Company is committed to leveraging its strategic assets in life insurance, wealth management, and healthcare to capitalize on emerging opportunities[297]. - The company is committed to purchasing 100% equity interest in Sony Life Financial Advisers Pte. Ltd. for a cash consideration of approximately US$1.88 million, with multiple extensions on the closing date[388]. Compliance and Regulatory - The company has received an exception period from Nasdaq to comply with listing requirements, with deadlines set for December 2025 and February 2026[288]. - Nasdaq granted the company an additional 180 days to regain compliance, which was achieved on May 3, 2024, confirming compliance with Rule 5550(a)(2)[389]. - The company has no off-balance sheet arrangements or guarantees beyond normal business operations[390]. Investments and Business Segments - The Company holds a 4% equity stake in HCMPS, which operates a network of over 800 doctors and provides healthcare schemes for more than 500 corporate clients[310][311]. - The Fintech Business includes investments in Tandem Money Limited ($17.75 million), CurrencyFair Limited ($5.89 million), and Goxip Inc. ($0.31 million) as of September 30, 2024[307]. - The Platform Business offers over 1,800 financial products, including 1,183 insurance products from 80 providers and 1,141 asset management products from 53 fund houses[304]. Losses and Financial Health - Net loss improved by 27.10%, from $12,921,000 in Q3 2023 to $9,419,000 in Q3 2024[316]. - Net loss decreased by US$3.5 million, or 27.10%, for the three months ended September 30, 2024, mainly due to a decrease in operating expenses[339]. - Net foreign exchange gain increased by US$2.0 million, or 227.89%, for the three months ended September 30, 2024, compared to a net foreign exchange loss in the same period of 2023[336]. - Net foreign exchange gain increased by US$0.8 million, or 1,914.63%, for the nine months ended September 30, 2024, due to a strong Sterling exchange rate[358]. - The company has an accumulated deficit of approximately US$94.4 million as of September 30, 2024[384].

Financial Performance - Total revenues decreased by 58.81% from $13,207,000 in Q3 2023 to $5,440,000 in Q3 2024[316]. - Total revenues for the nine months ended September 30, 2024, were US$18.0 million, a decrease of US$23.6 million, or 56.74%, compared to the same period in 2023[341]. - The Distribution Business contributed 84.43% of total revenue for the nine months ended September 30, 2024, with a significant revenue decrease of US$22.4 million, or 59.51%[342]. - Net loss for Q3 2024 was $9,419,000, a decrease of 27.10% compared to a net loss of $12,921,000 in Q3 2023[316]. - For the nine months ended September 30, 2024, the company reported a net loss of approximately US$28.8 million, with total revenue declining to approximately US$18.1 million from US$41.7 million in the same period of 2023[384][385]. Revenue Breakdown - Distribution Business revenue fell by 60.42%, from $11,876,000 in 2023 to $4,701,000 in 2024, contributing 86.42% of total revenue[318]. - Life insurance revenue decreased by 64.82%, from $11,147,000 in 2023 to $3,921,000 in 2024[319]. - The Company generated $15.21 million in commission from the Distribution Business for the nine months ended September 30, 2024[298]. Operating Expenses - Total operating expenses decreased by 36.36% from $24,550,000 in Q3 2023 to $15,623,000 in Q3 2024[316]. - Commission expense dropped by 78.31%, from $8,916,000 in 2023 to $1,934,000 in 2024[323]. - Personnel and benefit expenses decreased by 45.44%, from $6,446,000 in 2023 to $3,517,000 in 2024[328]. - Sales and marketing expense decreased by US$2.5 million, or 80.61%, from US$3.1 million in 2023 to US$0.6 million in 2024[347]. - Legal and professional fees decreased by US$7.0 million, or 56.35%, for the nine months ended September 30, 2024, primarily due to a reduction in consulting fees[352]. Cash Flow and Capital - As of September 30, 2024, the cash balance was US$5.1 million, with a working capital deficit of US$40.5 million, an increase of US$18.3 million or 82.21% from December 31, 2023[365][375]. - Net cash used in operating activities was US$20.7 million for the nine months ended September 30, 2024, compared to US$33.4 million for the same period in 2023[376]. - Net cash provided by investing activities for the nine months ended September 30, 2024, was US$2.6 million, primarily from the sale of long-term investments[379]. - Net cash provided by financing activities for the nine months ended September 30, 2024, was US$18.3 million, mainly due to advances from the holding company and proceeds from convertible promissory notes[381]. - The company intends to raise additional capital through various debt and equity offerings to support its operations and growth strategy[387]. Strategic Initiatives - The Company aims to transform JFA into the best medical care institution in Asia by 2025, focusing on technology and data analytics to enhance customer care[314]. - The Company plans to expand its distribution footprint in Mainland China and expects sales volumes to return to pre-pandemic levels with the reopening of the Mainland border[299]. - The Company is committed to leveraging its strategic assets in life insurance, wealth management, and healthcare to capitalize on emerging opportunities[297]. - The company is committed to purchasing 100% equity interest in Sony Life Financial Advisers Pte. Ltd. for a cash consideration of approximately US$1.88 million, with multiple extensions on the closing date[388]. Compliance and Governance - Nasdaq granted the company an additional 180 days to regain compliance, which was achieved on May 3, 2024, confirming compliance with Rule 5550(a)(2)[389]. - The company has no off-balance sheet transactions or guarantees beyond normal business operations[390].

Financial Performance - Net income for Q4 2025 was $24.8 million, or $0.88 per diluted share, compared to $16.4 million, or $0.58 per diluted share in Q4 2024[1][21] - Adjusted net income for Q4 2025 was $26.9 million, or $0.95 per diluted share, compared to $24.3 million, or $0.86 per diluted share in Q4 2024[1][3] - Net income for the year ended December 31, 2025, was $97,936,000, compared to $75,628,000 for the year ended December 31, 2024, reflecting a growth of 29.4%[57] - Diluted earnings per share for Q4 2025 was $0.88, compared to $0.58 in Q4 2024, indicating a significant increase of 51.7%[58] - Adjusted net income (non-GAAP) for the year ended December 31, 2025, was $100,505 thousand, compared to $87,744 thousand for the previous year, reflecting a year-over-year increase of 14.4%[72] - Adjusted diluted earnings per share (non-GAAP) rose to $3.56 for the year ended December 31, 2025, compared to $3.13 in 2024, marking an increase of 13.7%[73] Revenue and Income Sources - Total revenue for 2025 was $419.3 million, with net interest income of $317.4 million and noninterest income of $101.9 million[29][30] - Noninterest income for Q4 2025 totaled $26.7 million, representing 24.3% of total revenue[12][13] - Net interest income for Q4 2025 was $83,461,000, an increase from $77,047,000 in Q4 2024, representing a growth of 8.5% year-over-year[55] - Noninterest income for Q4 2025 reached $26,744,000, up from $21,635,000 in Q4 2024, marking a 23.5% increase[58] Asset and Loan Growth - Average loan growth was 8.5% annualized in Q4 2025, with total loans at $6.7 billion[5][17] - Total loans increased to $6.7 billion at December 31, 2025, up by $0.3 billion or 4.7% from $6.4 billion in 2024, driven by growth in C&I loans[34] - Total assets as of December 31, 2025, were $8,485,162,000, an increase from $8,097,387,000 as of December 31, 2024, representing a growth of 4.8%[57] Capital and Equity - Common equity tier 1 risk-based capital ratio was 14.12% as of December 31, 2025, indicating strong capital ratios[19] - Common equity tier 1 risk-based capital ratio stood at 14.12% as of December 31, 2025, with total risk-based capital ratio at 15.73% and tier 1 leverage ratio at 12.75%[36] - Book value per share increased to $41.36 at December 31, 2025, up by $3.78 from the previous year, while tangible book value per share rose to $37.83, an increase of $3.89[36] - Total stockholders' equity (GAAP) increased to $1,153,356 thousand as of December 31, 2025, compared to $1,041,366 thousand a year earlier, reflecting a growth of 10.74%[71] Efficiency and Management - The efficiency ratio for Q4 2025 was 65.37%, compared to 64.22% for the prior quarter[15] - The efficiency ratio for 2025 improved to 64.82% from 68.28% in 2024, while the adjusted efficiency ratio was 64.17% compared to 64.13% in 2024[32] - The efficiency ratio improved to 65.37% in Q4 2025 from 74.66% in Q4 2024, indicating better cost management[55] - Adjusted efficiency ratio (non-GAAP) improved to 63.36% in Q4 2025 from 64.00% in Q3 2025[74] Credit Quality - The provision for credit losses in 2025 was $24.6 million, a decrease of $3.0 million compared to 2024[26] - The company reported a provision for credit losses of $6,200,000 in Q4 2025, down from $10,100,000 in Q3 2025[59] - Nonperforming loans amounted to $60,771 as of December 31, 2025, down from $69,641 on September 30, 2025[70] - The ratio of nonperforming loans to total loans was 0.91% as of December 31, 2025, compared to 1.04% on September 30, 2025[70] Merger and Future Plans - The company is pursuing a merger with First Foundation Inc., with regulatory and stockholder approvals pending[46] - The anticipated benefits of the merger include cost savings and synergies, although there are risks associated with the integration process[46] - A conference call to discuss the fourth quarter and full year 2025 financial results is scheduled for January 27, 2026[41]

Financial Performance - Net sales for the three months ended December 27, 2025, were $3,189,693, a 59.0% increase from $2,006,348 for the same period in 2024[139] - Gross profit for the three months ended December 27, 2025, was $242,362, compared to $167,915 for the same period in 2024[139] - Selling, general and administrative expenses increased to $115 million for the three months ended December 27, 2025, from $71 million in the same period in 2024[143] - Research and development expenses were $9 million for the three months ended December 27, 2025, compared to $7 million for the same period in 2024[144] - Interest expense rose to $25 million for the three months ended December 27, 2025, from $5 million in the same period in 2024, primarily due to new term loans totaling $2.2 billion[146] - The effective tax rate for the three months ended December 27, 2025, was 16%, down from 18% in the same period in 2024, due to favorable discrete tax events[147] - Gross margin decreased to 7.6% for the three months ended December 27, 2025, from 8.4% for the same period in 2024[141] Cash Flow and Liquidity - Net cash provided by operating activities was $179 million for the three months ended December 27, 2025, compared to $63,938 for the same period in 2024, reflecting a significant increase[149] - Cash and cash equivalents increased to $1.4 billion as of December 27, 2025, up from $926 million as of September 27, 2025[152] - Working capital rose to $3.2 billion as of December 27, 2025, compared to $2.0 billion as of September 27, 2025[153] - Net cash used in investing activities was $1.4 billion, primarily for the ZT Acquisition, which accounted for the majority of the cash outflow[156] - Net cash provided by financing activities was $1.8 billion, including $2.2 billion borrowed for the ZT Acquisition[157] - The company believes existing cash resources and other sources of liquidity will be sufficient to meet working capital requirements for at least the next twelve months[169] Customer Concentration - Sales to the ten largest customers accounted for approximately 65% of net sales, with one customer representing 10% or more of net sales for the three months ended December 27, 2025[128] Strategic Initiatives - The company aims to diversify into mission-critical markets and develop higher technology products with longer life cycles[133] Shareholder Actions - The company repurchased 0.5 million shares of common stock for $79 million during the three months ended December 27, 2025[160] Accounts Receivable and Cash Cycle - Days in accounts receivable increased to 75 days as of December 27, 2025, compared to 60 days as of September 27, 2025[151] - The cash cycle days increased to 83 days as of December 27, 2025, compared to 57 days as of September 27, 2025[151] Tax Liabilities - As of December 27, 2025, the company had a liability of $50 million for uncertain tax positions[166]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to _________ Commission File Number: 001-43009 STARFIGHTERS SPACE, INC. (Exact name of registrant as specified in its charter) Delaware 92-1012 ...

Financial Performance - Net income for the fourth quarter of 2025 was $15.3 million, a decrease from $16.3 million in the third quarter of 2025 and $16.5 million in the fourth quarter of 2024[5]. - Diluted earnings per share for the fourth quarter of 2025 was $0.90, down from $0.96 in the previous quarter and the same quarter last year[5]. - Full year net income for 2025 was $58.5 million, compared to $49.7 million in 2024, representing a year-over-year growth of 17.6%[5]. - Net income for the quarter was $15,254,000, down from $16,318,000 in the prior quarter, representing a decrease of approximately 6.5%[26]. - Net income for the three months ended December 31, 2025, was $15,254,000, a decrease of 7.5% from $16,497,000 in the same period of 2024[33]. - Income before income taxes for the three months ended December 31, 2025, was $19,086,000, a decrease of 7.9% from $20,719,000 in the same period of 2024[33]. - Income tax expense for the twelve months ended December 31, 2025, was $15,602,000, compared to $13,575,000 in 2024, indicating an increase of 15.0%[33]. Asset and Liability Management - Total assets were $4.48 billion as of December 31, 2025, up from $4.23 billion a year earlier, reflecting a growth of 5.9%[5]. - Total assets as of December 31, 2025, reached $4,464,793 thousand, up from $4,302,079 thousand a year earlier[28]. - Total liabilities were $3,986,663,000 as of December 31, 2025, compared to $3,793,290,000 as of December 31, 2024, representing an increase of approximately 5.1%[32]. - Total stockholders' equity reached $493,837,000 as of December 31, 2025, compared to $494,949,000 as of December 31, 2024, showing a slight decrease of about 0.2%[32]. - Total stockholders' equity to total assets ratio improved to 11.02% from 10.67% in the prior quarter, reflecting stronger capital position[27]. Loan and Deposit Growth - Loans held for investment increased by $89.4 million, or 2.9%, during 2025, reaching $3.14 billion by year-end[5][11]. - Net loans held for investment amounted to $3,099,371,000 as of December 31, 2025, up from $3,001,817,000 as of December 31, 2024, indicating a growth of about 3.3%[32]. - Total loans held for investment as of December 31, 2025, amounted to $3,144,500,000, compared to $3,055,054,000 as of December 31, 2024[34]. - Demand deposits increased to $1,032,323 thousand as of December 31, 2025, compared to $978,742 thousand a year earlier[28]. - Total deposits as of December 31, 2025, were $3,874,007,000, an increase from $3,620,876,000 as of December 31, 2024[34]. Income and Expense Analysis - Noninterest income for the fourth quarter of 2025 was $10.9 million, a decrease from $11.2 million in the third quarter of 2025 and $13.3 million in the fourth quarter of 2024[9]. - Total noninterest income for the three months ended December 31, 2025, was $10,934,000, a decrease of 17.9% from $13,319,000 in the same period of 2024[33]. - Total noninterest expense for the twelve months ended December 31, 2025, was $132,620,000, an increase of 4.3% from $127,578,000 in 2024[33]. - Net interest income for the same quarter was $42,950,000, compared to $43,019,000 in the prior quarter, reflecting a slight decline[26]. - Net interest income after provision for credit losses for the twelve months ended December 31, 2025, was $161,804,000, up 13.3% from $142,798,000 in 2024[33]. Credit Quality and Provisioning - Provision for credit losses increased to $1,775,000 from $500,000 in the previous quarter, indicating a more cautious outlook on credit quality[26]. - Nonperforming loans stood at $9,805,000, a slight increase from $9,709,000 in the previous quarter, indicating potential credit quality concerns[26]. - Provision for credit losses for the twelve months ended December 31, 2025, was $5,195,000, compared to $4,300,000 in 2024, reflecting an increase of 20.8%[33]. Capital Position - Tangible book value per share increased over 14% to $29.05 at the end of 2025, compared to $25.40 at the end of 2024[3][5]. - The company has maintained a strong capital position with additional paid-in capital of $91,065,997 as of December 31, 2025, compared to $28,787,000 as of December 31, 2024, reflecting a substantial increase of approximately 216.5%[32]. - Tangible common equity increased to $473,389,000 in Q4 2025, compared to $457,222,000 in Q3 2025[36]. - Book value per share improved to $30.31 in Q4 2025 from $29.41 in Q3 2025[36].

Financial Performance - Net income for Q4 2025 was $55.5 million, or $1.06 per diluted share, up from $36.0 million, or $0.76 per diluted share in Q4 2024, and $54.5 million, or $1.03 per diluted share in Q3 2025 [2]. - Full year net income for 2025 was $169.2 million, or $3.33 per diluted share, compared to $140.6 million, or $2.97 per diluted share in 2024 [3]. - Operating diluted earnings per share for Q4 2025 was $1.05, compared to $0.77 in Q4 2024 [2]. - Diluted earnings per share for 2025 was $3.33, compared to $2.97 in 2024, reflecting a year-over-year increase [22]. - Return on average assets for 2025 was 1.11%, up from 1.04% in 2024 [22]. - Net income for 2025 reached $169,235,000, an increase from $140,641,000 in 2024, representing a growth of approximately 20.4% [29]. - Operating diluted earnings per share for 2025 was $3.82, compared to $2.94 in 2024, reflecting a year-over-year increase of 29.9% [29]. Asset and Loan Growth - Total assets were $16.00 billion as of December 31, 2025, with total deposits at $13.50 billion [17]. - Period end total loans were $11.60 billion, an increase of $1.63 billion, or 16.3%, from December 31, 2024 [7]. - Total loans increased to $11,598,114 thousand in Q4 2025 from $9,969,910 thousand in Q4 2024, reflecting a growth of approximately 16.3% year-over-year [24]. - Total assets increased to $16,086,195 thousand in Q4 2025, up from $15,988,299 thousand in Q3 2025, reflecting a growth of 0.61% [27]. - Average earning assets increased to $14,025,247,000 in 2025 from $12,449,064,000 in 2024, marking a rise of 12.7% [30]. Deposits and Equity - Total deposits increased by $1.95 billion, or 16.9%, from December 31, 2024, reaching $13.50 billion [7]. - Stockholders' equity increased by $370.1 million from December 31, 2024, driven by the Evans acquisition, net income generation of $169.2 million, and a decrease in accumulated other comprehensive loss [16]. - Total equity as of Q4 2025 was $1,896,216,000, up from $1,526,141,000 in Q4 2024, representing a growth of 24.2% [30]. Noninterest Income and Expenses - Noninterest income for Q4 2025 was $49.6 million, or 27% of total revenues, up $7.4 million, or 17.4%, from Q4 2024 [13]. - Total noninterest expense for Q4 2025 was $111,688, representing a 10.5% increase from $100,775 in Q4 2024 [25]. - Noninterest income for Q4 2025 reached $49,704, a 17.2% increase compared to $42,426 in Q4 2024 [25]. Interest Income and Margin - Total interest, fee, and dividend income for Q4 2025 was $188,544, an increase of 19.5% from $157,737 in Q4 2024 [25]. - Net interest income after provision for loan losses for Q4 2025 was $131,675, up 26.7% from $103,896 in Q4 2024 [25]. - Net interest margin (NIM) for Q4 2025 was 3.65%, a decrease of 1 basis point from the prior quarter [6]. - Net interest margin for 2025 was 3.59%, compared to 3.23% in 2024 [22]. - Net interest income for 2025 totaled $501,546,000, up from $400,122,000 in 2024, indicating a growth of 25.3% [30]. Acquisition and Growth Initiatives - The acquisition of Evans Bancorp added $1.67 billion in loans and $1.86 billion in deposits, with 200 new employees and 18 banking locations [4]. - Acquisition expenses for 2025 totaled $19,526,000, significantly higher than $1,531,000 in 2024, reflecting increased investment in growth initiatives [29]. Loan Quality and Allowance - The allowance for loan losses was $138.0 million, or 1.19% of total loans, at December 31, 2025, compared to $116.0 million, or 1.16% of total loans, at December 31, 2024 [10]. - Nonaccrual loans decreased to $44,592 thousand in Q4 2025 from $45,819 thousand in Q4 2024, a reduction of about 2.7% [23]. - Total nonperforming loans decreased to $51,723 thousand in Q4 2025 from $51,617 thousand in Q4 2024, showing a slight decline of 0.2% [23]. - The allowance for loan losses increased to $138,000 thousand in Q4 2025 from $116,000 thousand in Q4 2024, representing an increase of approximately 19.0% [24]. - The total nonperforming assets to total assets ratio remained stable at 0.33% in Q4 2025, unchanged from Q3 2025 [23].

Plant Closure and Restructuring - Tronox plans to permanently close its TiO2 plant in Fuzhou, China, with a capacity of 46,000 metric tons per year, due to weak domestic demand and rising production costs[1] - The company expects restructuring charges of approximately $60-80 million in Q4 2025, including $35-45 million in non-cash write-downs related to the shutdown[2] Financial Performance and Projections - For Q4 2025, Tronox anticipates revenue of $730 million, an 8% increase year-over-year, with $577 million from TiO2, $78 million from zircon, and $75 million from other products[3] - The expected net loss attributable to Tronox is $176 million, with Adjusted EBITDA projected at $57 million[5] - Free cash flow for Q4 2025 is expected to be $53 million, significantly exceeding guidance due to lower inventory levels[6] - The company will provide further details on its expectations for 2026 during the earnings call in February[6] Product Volume and Pricing - TiO2 volumes increased by 13% year-over-year and 9% sequentially, while zircon volumes rose by 27% year-over-year and 42% sequentially[4] - TiO2 pricing declined by 8% year-over-year, while zircon pricing fell by 23% year-over-year, primarily due to product mix[4] Strategic Initiatives - Tronox is advancing its minerals processing operations to produce rare earth elements, assessing the feasibility of a cracking and leaching facility in Australia[6] - The company aims to create a vertically-integrated supply chain for rare earth oxides, fulfilling its long-term sustainability strategy[6]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): January 26, 2026 ProPetro Holding Corp. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation) Delaware 001-38035 26-3685382 (Commission File Number) (I.R.S. Employer Identification No.) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) u ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-43007 BLUEROCK ACQUISITION CORP. (Exact Name of Registrant as Specified in Its Charter) Cayman Islands N/A (State or other jurisdiction ...